Showing 169–180 of 213 resultsSorted by latest
Pharma & Biotech
At the EUROGIN Congress, MRK announced plans for a new clinical program to develop a multi-valent HPV vaccine that aims to protect against a wider range of HPV types, particularly those affecting African and Asian populations.
Global expansion is a strategic focus for the company as it seeks to enhance net sales and market share.
The company is the global leader in cell culture media and single-use technology for producing biotech pharmaceuticals. It also has a rapidly growing purifying business. TMO has consistently outperformed the market for a long time, contributing significantly to growth.
LEQEMBI’s global sales increased significantly in the first quarter, hitting over $19 million, nearly tripling Q4FY23 results.
ABT is developing a new Alinity system to enter a market that it presently does not offer. In addition, the company has a good opportunity to reach emerging markets with biosimilars while remaining capital-efficient.
Novartis has made significant progress in its pipeline development and regulatory milestones, demonstrating its commitment to innovation and pipeline progression.
Twist Bioscience’s synthetic genes are a crucial part of its revenue stream, accounting for approximately 30% of total revenue.
Agilent Technologies has introduced the ProteoAnalyzer system, an innovative automated parallel capillary electrophoresis solution for protein analysis, which strengthens the company’s competitive positioning in the analytical instruments space.
Takeda Pharmaceutical’s increasing research and development (R&D) expenses potentially impacting its profitability and the importance of a robust product pipeline is supported by the provided sources.
The company has entered an exclusive development and commercialization deal with Coya Therapeutics for their investigational combination biologics for the treatment of neurodegenerative disease, ALS.
The company’s diversified segment, which includes the neurology, dermatology, and generics businesses, is subject to competitive and pricing pressures in diversified segments.
BioNTech reported a significant decline in its fourth-quarter profit and sales, which fell short of analysts’ expectations due to falling demand for COVID-19 vaccines. This decline was attributed to inventory write-downs by BioNTech’s collaboration partner, Pfizer.